Ascendis Pharma (ASND) Stock Forecast & Price Target

Ascendis Pharma is attractive because it combines a de-risked, multi-product rare-disease commercial base with meaningful pipeline optionality, led by YORVIPATH’s continued scaling, SKYTROFA’s durable recurring revenue, and YUVIWEL’s strong early launch momentum. The company reported more than 220 U.S. YUVIWEL enrollments through July 31 with >65% reimbursement approval, while YORVIPATH reached €252 million in 2Q26 and helped lift non-IFRS operating margin to 27% from 22% in 1Q26, underscoring improving operating leverage and cash generation. In addition, the settlement with BioMarin removes a major litigation overhang, and the TransCon platform, supported by later-stage hypochondroplasia and combination studies, extends long-term growth beyond the current franchise base.

Ascendis Pharma is viewed negatively because its growth depends on converting differentiated but still unproven products into durable reimbursement and prescribing, while YUVIWEL faces direct competition from BioMarin’s VOXZOGO in an established market. The company also carries meaningful execution and regulatory risk: YUVIWEL received accelerated approval and must verify clinical benefit, with final adult height, long-term safety, and broader clinical durability still open after only two years of trial data, while delayed EU review or unfavorable confirmatory findings could restrict use or jeopardize approval. Financially, management’s ability to drive revenue and operating leverage is threatened by slow paid starts, realized net price below gross WAC, reimbursement approvals stalling below 65%, and competitive pricing pressure that could limit share gains across its three franchises.